POINT BIOPHARMA GLOBAL INC (PNT) Stock Analyst Ratings
NASDAQ:PNT - Nasdaq - US7305411099 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 69% to PNT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 15.05. This target is 20.36% above the current price.
PNT was analyzed by 15 analysts. The buy percentage consensus is at 69. So analysts seem to be have mildly positive about PNT.
In the previous month the buy percentage consensus was at a similar level.
PNT was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-12-21 | Brookline Capital | Downgrade | Buy -> Hold |
| 2023-10-24 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-10-06 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2023-10-04 | JonesTrading | Downgrade | Buy -> Hold |
| 2023-10-04 | Truist Securities | Downgrade | Buy -> Hold |
| 2023-05-16 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2022-12-14 | Raymond James | Initiate | Outperform |
| 2022-11-30 | SVB Leerink | Initiate | Outperform |
| 2022-11-15 | Truist Securities | Maintains | Buy |
| 2022-10-11 | Oppenheimer | Initiate | Outperform |
| 2022-09-16 | Truist Securities | Initiate | Buy |
| 2022-09-14 | Berenberg | Initiate | Buy |
| 2022-09-07 | JonesTrading | Initiate | Buy |
| 2022-08-16 | Guggenheim | Initiate | Buy |
| 2022-07-06 | William Blair | Initiate | Outperform |
| 2022-05-26 | Jefferies | Upgrade | Hold -> Buy |
| 2021-12-17 | Mizuho | Initiate | Underperform |
| 2021-07-29 | Cowen & Co. | Initiate | Outperform |
| 2021-07-27 | Jefferies | Initiate | Hold |
| 2021-07-26 | Piper Sandler | Initiate | Overweight |